scispace - formally typeset
K

Katsutoshi Goto

Researcher at University of Tsukuba

Publications -  231
Citations -  31742

Katsutoshi Goto is an academic researcher from University of Tsukuba. The author has contributed to research in topics: Endothelin 1 & Endothelin receptor. The author has an hindex of 63, co-authored 228 publications receiving 31015 citations. Previous affiliations of Katsutoshi Goto include University of Texas Southwestern Medical Center.

Papers
More filters
Journal ArticleDOI

An Endothelin Type A Receptor Antagonist Reverses Upregulated VEGF and ICAM-1 Levels in Streptozotocin-Induced Diabetic Rat Retina

TL;DR: ETA receptor antagonist might be useful in preventing the progression of diabetic retinopathy, as evidenced by suppressing the increase in VEGF and ICAM-1 levels as well as leukostasis in morphologically intact diabetic retina.
Journal ArticleDOI

Gastric mucosal injury induced by local ischemia-reperfusion in rats : Role of endogenous endothelin-1 and free radical

TL;DR: The greater protection observed with bosentan than with radical scavengers might reflect a preferential role of endothelin-1 in this type of injury.
Journal ArticleDOI

Activin A Stimulates Mitogenesis in Swiss 3T3 Fibroblasts without Activation of Mitogen-activated Protein Kinases*

TL;DR: The observations strongly suggest that the activation of mitogen-activated protein kinase is not a necessary step for activin A-induced DNA synthesis in Swiss 3T3 fibroblasts.
Journal ArticleDOI

SB209670, a potent endothelin receptor antagonist, prevents or delays axonal degeneration after spinal cord injury

TL;DR: Results suggest that endogenous endothelin plays a role in axonal degeneration after spinal cord injury and that SB209670 prevents or delays the axonaldegeneration after CNS damage.
Journal ArticleDOI

Activation of Peroxisome Proliferator-activated Receptor-α Decreases Endothelin-1-induced p38 Mitogen-activated Protein Kinase Activation in Cardiomyocytes

TL;DR: The results suggest that the negative effect of the PPAR-α activator, fenofibrate, on ET-1-induced cardiac hypertrophy may be partly due to inhibition of the p38 signaling pathway.